
Opinion|Videos|March 18, 2024
CARTITUDE-4 Study: Ciltacabtagene Autoleucel in R/R MM
Author(s)Binod Dhakal, MD, MS
Binod Dhakal, MD, reviews the latest results from the CARTITUDE-4 study, which evaluated ciltacabtagene autoleucel (cilta-cel) versus standard of care in patients with R/R MM, including study design, patient population, and key efficacy findings.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
4
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
5


















